If you haven’t read it yet👇 Sample Size and Power Calculations Based on Endpoint Responsiveness: Applications to Trials of Disease-Modifying Therapies in Parkinson’s Disease www.medrxiv.org/content/10.6...

Show Post

It was a really successful International Parkinson and Movement Disorder Society congress in Seoul this year for Indivi #MDSCongress #MDS2026

Show Post

Do all DM1 therapies need to be oligonucleotides? What about: -> small molecules? -> engineered RNA-binding proteins? -> gene and repeat targeting? -> drug repurposing? Future DM1 therapies discussed at #WMS2026 will extend beyond oligonucleotides alone

Show Post

In his #WMS2026 talk "Advances in Translational Therapeutics for DM1," Prof. Masayuki Nakamori (Yamaguchi University) highlighted how quickly the DM1 pipeline has matured, and also what remains to be solved: the endpoint

Show Post

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease www.thelancet.com/journals/ebi...

Show Post